Antisense Reduction of Tau in Adult Mice Protects against Seizures

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Neuroscience

• Publication date

  2013-07-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1523/JNEUROSCI.2107-13.2013PMID 23904623PMCID PMC3728694
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tau protein concentrations in the cerebrospinal fluid of children with acute disseminated encephalomyelitis.

  2014cited by this paper
• GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.

  2013cited by this paper
• An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

  2013cited by this paper
• Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA

  2013influential reference
• Seizures and epileptiform activity in the early stages of Alzheimer disease.

  2013cited by this paper
• Physiological release of endogenous tau is stimulated by neuronal activity

  2013cited by this paper
• Amyloid-&bgr; signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer's disease

  2013cited by this paper
• Age-appropriate cognition and subtle dopamine-independent motor deficits in aged tau knockout mice.

  2013cited by this paper
• Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

  2013influential reference
• Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy

  2013influential reference
• Physiological Brain Activity Causes DNA Double Strand Breaks in Neurons — Exacerbation by Amyloid-β

  2013influential reference
• Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model

  2012cited by this paper
• MAPT expression and splicing is differentially regulated by brain region: relation to genotype and implication for tauopathies

  2012cited by this paper
• Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

  2012cited by this paper
• Transcompartmental reversal of single fibre hyperexcitability in juxtaparanodal Kv1.1‐deficient vagus nerve axons by activation of nodal KCNQ channels

  2012cited by this paper
• A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.

  2012cited by this paper
• Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice.

  2012cited by this paper
• Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export

  2012cited by this paper
• Patterns of treatment response in newly diagnosed epilepsy

  2012cited by this paper
• Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice.

  2012cited by this paper
• Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.

  2012cited by this paper
• Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease

  2011influential reference
• Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

  2011cited by this paper
• In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice

  2011influential reference
• Neuronal activity regulates the regional vulnerability to amyloid-β deposition

  2011cited by this paper
• Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs.

  2011cited by this paper
• Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain.

  2011cited by this paper
• Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers

  2011cited by this paper
• Stroke: Predicting the risk of poststroke epilepsy—why and how?

  2010cited by this paper
• Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport

  2010cited by this paper
• Kv1.1 Potassium Channel Deficiency Reveals Brain-Driven Cardiac Dysfunction as a Candidate Mechanism for Sudden Unexplained Death in Epilepsy

  2010cited by this paper
• ApoE epsilon4 genotype and the age at onset of temporal lobe epilepsy: a case-control study and meta-analysis.

  2010cited by this paper
• Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease.

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform.

  2010cited by this paper
• Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection

  2010cited by this paper
• Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

  2010cited by this paper
• Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice

  2010cited by this paper
• Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy

  2010cited by this paper
• Faculty Opinions recommendation of Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.

  2009cited by this paper
• CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease

  2009cited by this paper
• Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly

  2009cited by this paper
• Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure.

  2009cited by this paper
• Efficacy of systemic morpholino exon‐skipping in duchenne dystrophy dogs

  2009cited by this paper
• Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

  2009cited by this paper
• Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition

  2008cited by this paper
• Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo.

  2008cited by this paper
• Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14.

  2007cited by this paper
• The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts.

  2007cited by this paper
• Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  2007influential reference
• Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice.

  2007cited by this paper
• Cerebellar synaptic defects and abnormal motor behavior in mice lacking alpha- and beta-dystrobrevin.

  2006cited by this paper
• Cerebellar Synaptic Defects and Abnormal Motor Behavior in Mice Lacking α- and β-Dystrobrevin

  2006cited by this paper
• Picrotoxin-like channel blockers of GABAA receptors.

  2006influential reference
• Incidence and Predictors of Seizures in Patients with Alzheimer's Disease

  2006cited by this paper
• Antisense oligonucleotide therapy for neurodegenerative disease.

  2006cited by this paper
• Seizures and Epilepsy After Ischemic Stroke

  2004cited by this paper
• Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults.

  2004cited by this paper
• Pathways towards and away from Alzheimer's disease

  2004cited by this paper
• The Apolipoprotein E Epsilon (epsilon) 4 Allele Is Important for Trauma-related Epilepsy.

  2004cited by this paper
• The Apolipoprotein E Epsilon (∊) 4 Allele is Important for Trauma-Related Epilepsy

  2004cited by this paper
• Gene regulation and DNA damage in the ageing human brain

  2004cited by this paper
• CA1 Hippocampal Neuronal Loss in Familial Alzheimer's Disease Presenilin‐1 E280A Mutation Is Related to Epilepsy

  2004cited by this paper
• Seizures in Elderly Patients with Dementia

  2003cited by this paper
• Solid Phase Synthesis of Phosphorothioate Oligonucleotides Utilizing Diethyldithiocarbonate Disulfide (DDD) as an Efficient Sulfur Transfer Reagent

  2003influential reference
• Ectopic White Matter Neurons, a Developmental Abnormality That May Be Caused by the PSEN1 S169L Mutation in a Case of Familial AD with Myoclonus and Seizures

  2001cited by this paper
• Neurotrophins are required for nerve growth during development

  2001cited by this paper
• Altered Stress-Induced Anxiety in Adenylyl Cyclase Type VIII-Deficient Mice

  2000cited by this paper
• Excitotoxic neurodegeneration in Alzheimer disease

  2000cited by this paper
• Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice.

  2000cited by this paper
• The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures.

  2000cited by this paper
• Patients with refractory seizures.

  1999cited by this paper
• Characterization of a Potent and Specific Class of Antisense Oligonucleotide Inhibitor of Human Protein Kinase C-α Expression*

  1999influential reference
• Comparative Biochemistry of Tau in Progressive Supranuclear Palsy, Corticobasal Degeneration, FTDP‐17 and Pick's Disease

  1999cited by this paper
• A population-based study of seizures after traumatic brain injuries.

  1998cited by this paper
• Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies.

  1997cited by this paper
• Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

  1997cited by this paper
• The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes.

  1997cited by this paper
• Tau Binds to the Distal Axon Early in Development of Polarity in a Microtubule- and Microfilament-Dependent Manner

  1996cited by this paper
• Altered microtubule organization in small-calibre axons of mice lacking tau protein

  1994cited by this paper
• A Tau antisense oligonucleotide decreases neurone sensitivity to excitotoxic injury.

  1993cited by this paper
• The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices.

  1991cited by this paper
• Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer

  1985cited by this paper
• Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurones

  1977cited by this paper
• Modification of seizure activity by electrical stimulation: cortical areas.

  1975cited by this paper
• A protein factor essential for microtubule assembly.

  1975cited by this paper
• Chemical pathology of neurofibrils. Neurofibrillary tangles of Alzheimer's presenile-senile dementia.

  1975cited by this paper
• Modification of seizure activity by electrical stimulation. II. Motor seizure.

  1972influential reference
• ARE GENES THE PRODUCT OF CROSSING-OVER.

  1933cited by this paper

• Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease

  2026cites this paper
• Excitation-inhibition homeostasis in Alzheimer's disease: a selective multiscale review of mechanisms, sex differences, and therapeutic opportunities.

  2026cites this paper
• Antecedent enhancer activity predicts future susceptibility to seizures in mice

  2026cites this paper
• Aging and Alzheimer’s: the critical role of mitochondrial dysfunction and synaptic alterations

  2026cites this paper
• AAV delivery of artificial miRNA targeting MAPT for the reduction of tau pathology in Alzheimer’s disease

  2025cites this paper
• IgLON5 autoimmune antibodies activate Tau via neuronal hyperactivity

  2025cites this paper
• Hippocampus and amygdala volume and morphology in neurodegenerative disorders with co-morbid epilepsy

  2025cites this paper
• Differential effects of tau expression on seizures and epileptogenesis in a mouse model of temporal lobe epilepsy

  2025cites this paper
• Excitation-inhibition imbalance as a common thread linking early Alzheimer's disease with temporal lobe epilepsy.

  2025cites this paper
• Seeding Alzheimer’s disease-associated tau pathology in MAPT knock-in primary neurons causes early axonopathy and synaptic dysfunction

  2025cites this paper
• Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.

  2025cites this paper
• [Epileptic seizures in patients with Alzheimer's disease].

  2025cites this paper
• Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference

  2025cites this paper
• Tau drives cell specific functional isolation of the hippocampal formation

  2025cites this paper
• Protein Misfolding and Aggregation in the Pathogenesis of Alzheimer’s Disease

  2025cites this paper
• A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies

  2025cites this paper
• Distinct manifestations of excitatory-inhibitory imbalance associated with amyloid-β and tau in patients with Alzheimer’s disease

  2025cites this paper
• Exploring biomarkers of neurodegeneration in epilepsy: Critical insights

  2025cites this paper
• Prior epigenetic status predicts future susceptibility to seizures in mice

  2025cites this paper
• Decoding the role of microtubules: a trafficking road for vesicle

  2025cites this paper
• 4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy

  2025cites this paper
• The evolving landscape of Alzheimer's disease therapy: From Aβ to tau.

  2025cites this paper
• MAPT Splicing Modulators as a Therapeutic Strategy for Tauopathies

  2025cites this paper
• Updates on tau-related drug targets and potential disease-modifying therapies for Alzheimer's disease.

  2025cites this paper
• Synergistic Effect between the APOE ε4 Allele with Genetic Variants of GSK3B and MAPT: Differential Profile between Refractory Epilepsy and Alzheimer Disease

  2024cites this paper
• Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.

  2024cites this paper
• Characterization of tau propagation pattern and cascading hypometabolism from functional connectivity in Alzheimer's disease

  2024cites this paper
• A Mutual Nexus Between Epilepsy and α-Synuclein: A Puzzle Pathway

  2024cites this paper
• Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures

  2024cites this paper
• Cellular and pathological functions of tau

  2024cites this paper
• Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system

  2024cites this paper
• Chronic Neuronal Hyperexcitation Exacerbates Tau Propagation in a Mouse Model of Tauopathy

  2024cites this paper
• Multi-omic phenotyping of iPSC-derived neurons harboring the MAPT V337M mutation reveals tau hypophosphorylation and perturbed axon morphology pathways

  2024cites this paper
• Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease.

  2024cites this paper
• Latest advances in mechanisms of epileptic activity in Alzheimer’s disease and dementia with Lewy Bodies

  2024cites this paper
• Astrocyte-Neuron Interactions in Alzheimer's Disease.

  2024cites this paper
• Excitoprotective effects of conditional tau reduction in excitatory neurons and in adulthood

  2024cites this paper
• Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model

  2024influential citation
• Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums

  2024cites this paper
• Structural and functional remodeling of neural networks in β-amyloid driven hippocampal hyperactivity.

  2024cites this paper
• Enhanced Fyn-tau and NR2B-PSD95 interactions in epileptic foci in experimental models and human epilepsy

  2024cites this paper
• The six brain‐specific TAU isoforms and their role in Alzheimer's disease and related neurodegenerative dementia syndromes

  2024cites this paper
• Present Insights into the progress in gene therapy delivery systems for central nervous system diseases.

  2024cites this paper
• Association of Seizure Control With Cognition in People With Normal Cognition and Mild Cognitive Impairment

  2024cites this paper
• Personalized virtual brains of Alzheimer's Disease link dynamical biomarkers of fMRI with increased local excitability

  2023cites this paper
• Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?

  2023cites this paper
• Excitatory: inhibitory imbalance in Alzheimer’s disease is exacerbated by seizures with attenuation after rapamycin treatment in 5XFAD mice

  2023cites this paper
• Progressive Dysregulation of Tau Phosphorylation in an Animal Model of Temporal Lobe Epilepsy.

  2023cites this paper
• Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

  2023cites this paper
• Etiology and Clinical Significance of Network Hyperexcitability in Alzheimer’s Disease: Unanswered Questions and Next Steps

  2023cites this paper
• Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability

  2023cites this paper
• Advances in Nucleic Acid Research: Exploring the Potential of Oligonucleotides for Therapeutic Applications and Biological Studies

  2023cites this paper
• Evaluating the efficacy of purchased antisense oligonucleotides to reduce mouse and human tau in vivo

  2023influential citation
• Tau reduction attenuates autism-like features in Fmr1 knockout mice

  2023influential citation
• Tackling seizures in patients with Alzheimer’s disease

  2023cites this paper
• Multivalent Tau/PSD-95 interactions arrest in vitro condensates and clusters mimicking the postsynaptic density

  2023cites this paper
• Prevalence and localization of nocturnal epileptiform discharges in mild cognitive impairment

  2023cites this paper
• Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer’s Disease: Recent Trends and Future Development

  2023influential citation
• Connectome-based modelling of neurodegenerative diseases: towards precision medicine and mechanistic insight

  2023cites this paper
• Blood tau‐PT217 contributes to the anesthesia/surgery‐induced delirium‐like behavior in aged mice

  2023cites this paper
• β_2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice

  2023cites this paper
• Targeting epigenetics: A novel promise for Alzheimer's disease treatment.

  2023cites this paper
• Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology

  2023cites this paper
• The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies

  2023cites this paper
• Phospholipase D1 Attenuation Therapeutics Promotes Resilience against Synaptotoxicity in 12-Month-Old 3xTg-AD Mouse Model of Progressive Neurodegeneration

  2023cites this paper
• Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics

  2023cites this paper
• New insights into the therapeutic approaches for the treatment of tauopathies

  2023cites this paper
• Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer’s disease with attenuation after rapamycin treatment in 5XFAD mice.

  2023cites this paper
• Evaluating the efficacy of commercially available antisense oligonucleotides to reduce mouse and human tau in vivo

  2022influential citation
• Neuronal hyperexcitability in the Tg2576 mouse model of Alzheimer's disease - the influence of sleep and noradrenergic transmission.

  2022cites this paper
• Tau kinetics in Alzheimer's disease

  2022cites this paper
• Revisiting the involvement of tau in complex neural network remodeling: analysis of the extracellular neuronal activity in organotypic brain slice co-cultures

  2022cites this paper
• Amyloid-β in Alzheimer’s disease – front and centre after all?

  2022cites this paper
• The role of peptidyl-prolyl isomerase Pin1 in neuronal signaling in epilepsy

  2022cites this paper
• The reduction of astrocytic tau prevents amyloid-β-induced synaptotoxicity

  2022cites this paper
• One to Rule Them All: A Unique TAU Therapy for Neurodevelopmental Encephalopathies

  2022cites this paper
• Early impairments of visually-driven neuronal ensemble dynamics in the rTg4510 tauopathy mouse model

  2022cites this paper
• Proteomic Assessment of C57BL/6 Hippocampi after Non-Selective Pharmacological Inhibition of Nitric Oxide Synthase Activity: Implications of Seizure-like Neuronal Hyperexcitability Followed by Tauopathy

  2022cites this paper
• Neuronal hyperexcitability in Alzheimer’s disease: what are the drivers behind this aberrant phenotype?

  2022cites this paper
• Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs

  2022cites this paper
• Pyramidal cell axon initial segment in Alzheimer´s disease

  2022cites this paper
• Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.

  2022cites this paper
• Understanding the neurophysiological consequences of Alzheimer’s disease pathology

  2022influential citation
• A mechanistic study on the cellular uptake, intracellular trafficking, and antisense gene regulation of bottlebrush polymer-conjugated oligonucleotides

  2022cites this paper
• Quantifying and Mitigating Motor Phenotypes Induced by Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System Antisense Oligonucleotides in the Central Nervous System

  2022cites this paper
• TAU ablation in excitatory neurons and postnatal TAU knockdown reduce epilepsy, SUDEP, and autism behaviors in a Dravet syndrome model

  2022cites this paper
• Can rapamycin slow down memory decline in Alzheimer's disease with seizures?

  2022cites this paper
• Targeted degradation of microtubule-associated protein tau using an engineered nanobody-E3 ubiquitin ligase adapter fusion

  2022cites this paper
• Sleep: The Tip of the Iceberg in the Bidirectional Link Between Alzheimer's Disease and Epilepsy

  2022cites this paper
• Seizure activity triggers tau hyperphosphorylation and amyloidogenic pathways

  2022cites this paper
• Microtubules as Regulators of Neural Network Shape and Function: Focus on Excitability, Plasticity and Memory

  2022cites this paper
• Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaques.

  2022cites this paper
• Epilepsy in neurodegenerative diseases.

  2022cites this paper
• Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms

  2022cites this paper
• Postictal Death Is Associated with Tonic Phase Apnea in a Mouse Model of Sudden Unexpected Death in Epilepsy

  2021cites this paper
• Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System

  2021cites this paper
• Retromer dysfunction at the nexus of tauopathies

  2021cites this paper
• Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases.

  2021cites this paper
• Severe oligomeric tau toxicity can be reversed without long-term sequelae

  2021cites this paper
• Targeted Reducing of Tauopathy Alleviates Epileptic Seizures and Spatial Memory Impairment in an Optogenetically Inducible Mouse Model of Epilepsy

  2021cites this paper